Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 12, 2016, Pages 3495-3505

  Zhou, Nannan ^a   Han, Zhou ^a   Hartman Neumann, Sandra ^a   DeGray, Brenda ^a   Ueland, Joseph ^a   Vellucci, Vincent ^a   Hernandez, Dennis ^a   McPhee, Fiona ^a  

^a BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DACLATASVIR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ARTICLE; COMPARATIVE STUDY; DNA POLYMORPHISM; DRUG POTENCY; DRUG TREATMENT FAILURE; EC50; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHYLOGENY; PREVALENCE; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CLASSIFICATION; CLINICAL TRIAL (TOPIC); EUROPE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MISSENSE MUTATION; UNITED STATES; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; EUROPE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; UNITED STATES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85012086800     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/JAC/DKW336     Document Type: Article

References (50)

1. Smith DB, Bukh J, Kuiken C et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-27
2. Messina JP, Humphreys I, Flaxman A et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87
3. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014; 348: g3308
4. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16
5. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206
6. Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13
7. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88
8. Manns M, Pol S, Jacobson IM et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-605
9. Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013; 22: 1107-21
10. Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol 2014; 30: 217-22
11. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87
12. Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44
13. Dore GJ, Lawitz E, Hezode C et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 2015; 148: 355-66 e1
14. Chayama K, Notsumata K, Kurosaki M et al. Randomized trial of interferon-and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 2015; 61: 1523-32
15. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21
16. SOVALD(R) [package insert]. Gilead Sciences, Inc., Foster City, CA; August 2015. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
17. Hezode C, Hirschfield GM, GhesquiereWet al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015; 64: 948-56
18. Poveda E, Wyles DL, Mena A et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 2014; 108: 181-91
19. Gao M, Nettles RE, BelemaMet al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100
20. Pol S. Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virological data, treatment rationale and clinical trials. Clin Invest 2013; 3: 191-207
21. Poordad F, SchiffER, Vierling JM et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63: 1493-505
22. Wyles DL, Ruane PJ, Sulkowski MS et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 714-25
23. Nelson DR, Cooper JN, Lalezari JP et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-35
24. Leroy V, Angus P, Bronowicki JP et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016; 63: 1430-41
25. Foster G, Chayama K, Chuang Wet al. Efficacy and safety of peginterferon lambda 1a with or without daclatasvir compared with peginterferon alfa 2a each in combination with ribavirin in treatment naive patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology Int 2015; 9: S259
26. Kuiken C, Yusim K, Boykin L et al. The Los Alamos hepatitis C sequence database. Bioinformatics 2005; 21: 379-84
27. Kato T, Furusaka A, Miyamoto M et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001; 64: 334-9
28. Tamura K, Stecher G, Peterson D et al. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013; 30: 2725-9
29. McPhee F, Hernandez D, Yu F et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013; 58: 902-11
30. Fridell RA, Qiu D, Wang C et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54: 3641-50
31. Fridell RA, Qiu D, Valera L et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011; 85: 7312-20
32. Eley T, Sevinsky H, Huang SP et al. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus. Clin Drug Investig 2014; 34: 661-71
33. Lam AM, Espiritu C, Bansal S et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56: 3359-68
34. Liu M, Tuttle M, GaoM et al. Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes. Antimicrob Agents Chemother 2014; 58: 7416-23
35. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32: 2117-38
36. Susser S, Dietz J, Barak M et al. Prevalence and clinical importance of hepatitis C virus genotype 2 k/1b chimeras. J Hepatol 2016; 64: S136
37. Morel V, Fournier C, Francois C et al. Genetic recombination of the hepatitis C virus: clinical implications. J Viral Hepat 2011; 18: 77-83
38. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-35
39. Wang C, Sun JH, O'Boyle DR 2nd et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 2013; 57: 2054-65
40. McPhee F, Suzuki Y, Toyota J et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv Ther 2015; 32: 637-49
41. Hernandez D, Zhou N, Ueland J et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 2013; 57: 13-8
42. Wong KA, Worth A, Martin R et al. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 2013; 57: 6333-40
43. Kumari R, Nguyen MH. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert Opin Pharmacother 2015; 16: 739-48
44. Bilello JP, Lallos LB, McCarville JF et al. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2014; 58: 4431-42
45. Bartolini B, Lionetti R, Giombini E et al. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing. J Clin Virol 2015; 66: 38-43
46. Zhou N, Hernandez D, Ueland J et al. NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection. J Infect Dis 2016; 213: 206-15
47. Deeks ED. Ombitasvir/paritaprevir/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection. Drugs 2015; 75: 1027-38
48. Zepatier(R) [package insert]. Merck & Co., Kenilworth, NJ; January 2016. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf
49. Keating GM. Elbasvir/Grazoprevir: first global approval. Drugs 2016; 76: 617-24
50. Backus LI, Belperio PS, Shahoumian TA et al. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 2015; 42: 559-73